ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2611

Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)

Keisuke Izumi1, Misato Hashizume2, Yuko Kaneko3, Keiko Yoshimoto1 and Tsutomu Takeuchi1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Product Research Department, Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 3Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, cytokines, interstitial lung disease, monocytes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose : Interstitial pneumonia (IP) is one of the most critical complications in rheumatoid arthritis (RA). Severe IP is developed in zymosan-treated SKG mice, and this IP is completely blocked by neutralization of granulocyte macrophage colony-stimulating factor (GM-CSF) (Shiomi A, et al. J Immunol. 2014;15;193(2):849-59). GM-CSF induces expression of soluble vascular endothelial growth factor (VEGF) receptor-1 from human monocytes (Eubank TD, et al. Immunity. 2004;21(6):831-42). Here we aimed to explore the associations between IP and biomarkers including GM-CSF, VEGF, and circulating monocyte count in biologic-naive patients with RA.

Methods : Consecutive biologic-naive patients with RA were enrolled in our prospective cohort study at the timing of initiating biologics. Our cohort started in February 2010, and the patients were analysed as of April 2012. Before initiating biologics, we evaluated chest X-rays for all of the patients, and if IP was suspected, a chest computed tomographic (CT) scan was taken. At the enrollment of our cohort we assessed variables including the patients’ characteristics (sex, age, disease duration, prednisolone dose, methotrexate dose, Clinical Disease Activity Index, Health Assessment Questionnaire-Disability Index) and blood biomarkers (GM-CSF [pg/mL], VEGF [pg/mL], TNF-α [pg/mL], Interleukin(IL)-6 [pg/mL], IL-17 [pg/mL], osteopontin [ng/mL], C-reactive protein [mg/dL], white blood cell count [/μL], neutrophil count [/μL], and monocyte count [/μL]) to extract factors associated with CT scan-proven IP using univariate analyses. The extracted factors were entered into a multivariate logistic regression model to obtain factors associated with IP.

Results : A total of 127 patients (108 females and 19 males) were included in our study. The mean age and disease duration of the patients were 56.2±12.9 years and 6.7±7.7 years, respectively. CT scan-proven IP was noted in 17 patients. Prednisolone was used in 33 patients and methotrexate was used in 110. In the univariate analyses, sex, age, prednisolone dose, methotrexate dose, GM-CSF, VEGF, and monocyte count were significantly associated with IP (P<0.05). In the multivariate analyses, age (OR 1.081, 95% CI 1.010-1.174), methotrexate dose (OR 0.820, 95% CI 0.686-0.970), and monocyte count (OR 1.005, 95% CI 1.001-1.010) were identified as factors associated with IP.

Conclusion : The large number of circulating monocytes as well as advanced age and low methotrexate dose is significantly associated with IP in biologic-naive patients with RA.


Disclosure: K. Izumi, None; M. Hashizume, Chugai Pharmaceutical Co., Ltd., 3; Y. Kaneko, Abbvie, 5,Abbvie, Eisai Pharmaceutical, Chugai Pharmaceutical, Bristol Myers Squibb, Astellas Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Pfizer, Janssen, UCB., 8,Eisai Pharmaceutical, Chugai, Pharmaceutical, Astellas Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Pfizer, 9; K. Yoshimoto, None; T. Takeuchi, Astellas Pharma Inc, Bristol-Myers KK, Chugai Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Eisai Co, Ltd, Mitsubishi Tanabe Pharma Corp, Pfizer Japan, Santen Pharmaceutical Co, Ltd, Takeda Pharmaceutical Co, Ltd, Teijin Pharma Ltd, AbbVie GK, Asahi Kas, 2,AbbVie GK, Bristol-Myers KK, Chugai Pharmaceutical Co, Ltd, Eisai Co, Ltd, Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corp, Pfizer Japan Inc, Takeda Pharmaceutical Co, Ltd, Astellas Pharma Inc, and Daiichi Sankyo Co, Ltd; and consultant fees from, 8.

To cite this abstract in AMA style:

Izumi K, Hashizume M, Kaneko Y, Yoshimoto K, Takeuchi T. Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/circulating-monocyte-count-is-significantly-associated-with-interstitial-pneumonia-in-biologic-naive-patients-with-rheumatoid-arthritis-a-single-center-prospective-cohort-study-keio-first-bio-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-monocyte-count-is-significantly-associated-with-interstitial-pneumonia-in-biologic-naive-patients-with-rheumatoid-arthritis-a-single-center-prospective-cohort-study-keio-first-bio-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology